Introgen has received a U.S. patent for the production of its adenoviral cancer treatment Advexin, Introgen said.
Adenoviral therapy uses genetically modified viruses found in DNA. The viruses can be modified to treat cancer and other diseases.
Introgen said the patent "broadly covers all adenoviral p53 manufacturing methods." Advexin p53 is a targeted molecular therapy that targets abnormal tumor suppressor function, associated with cancer initiation, progress and treatment resistance.